Saturday 7 November 2026
Export LNTH’s income statement to Excel — free account
Lantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −16.4%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
100.65
0.05
−0.05%
Follow LNTH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
24.03 | 26.35 | 18.02 | 19.35 |
+8 more quarters Free account |
P/S ratio |
4.16 | 4.64 | 3.18 | 2.91 | |
P/FCF ratio |
16.53 | 18.40 | 12.85 | 12.69 | |
P/Operating CF |
63.73 | 78.40 | 39.24 | 49.81 | |
P/B ratio |
4.95 | 5.51 | 4.05 | 4.12 | |
Price to Tangible BV |
15.06 | 18.85 | 18.40 | 35.23 | |
EV/Sales |
4.09 | 4.63 | 3.22 | 3.05 | |
EV/EBITDA |
16.53 | 18.23 | 13.33 | 12.20 | |
EV/Operating CF |
15.60 | 17.46 | 12.22 | 12.05 | |
EV/FCF |
16.25 | 18.35 | 13.04 | 13.28 | |
Quick Ratio |
2.98 | 2.82 | 2.57 | 2.20 | |
Current Ratio |
3.25 | 3.06 | 2.83 | 2.70 | |
Net Debt/EBITDA |
0.00 | (0.18) | 0.68 | 2.08 | |
Debt/Assets |
23.28% | 23.65% | 24.31% | 25.56% | |
Debt/Equity |
0.42 | 0.44 | 0.47 | 0.52 | |
Asset Turnover |
0.66 | 0.69 | 0.70 | 0.73 | |
Operating CF/Net income |
4.56 | 1.23 | 1.06 | 1.67 | |
Capex/Depreciation |
0.00 | (0.10) | 0.07 | (0.37) | |
Interest Coverage |
6.52 | 20.39 | 16.72 | 15.20 | |
Research and Development Expense of Revenue |
23.79% | 9.84% | 10.44% | 11.67% | |
Selling, General and Administrative Expense of Revenue |
30.38% | 26.65% | 29.21% | 28.57% | |
Intangible Assets out of Total Assets |
0.36 | 0.38 | 0.40 | 0.43 | |
Share Based Compensation of Revenue |
0.00% | 5.15% | 4.25% | 4.31% | |
Graham Net Nets |
0.00 | (0.01) | (0.04) | (0.05) | |
Graham Number |
0.00 | 43.67 | 42.12 | 35.35 | |
Earnings Yield |
4.16% | 3.79% | 5.55% | 5.17% | |
Free Cash Flow Yield |
6.05% | 5.43% | 7.78% | 7.88% | |
Revenue per Share |
5.97 | 5.96 | 5.83 | 6.03 | |
Operating CF per Share |
1.56 | 1.42 | 1.93 | 1.34 | |
Capex per Share |
(0.11) | (0.04) | 0.03 | (0.13) | |
Free Cash Flow per Share |
1.45 | 1.38 | 1.96 | 1.21 | |
Cash per Share |
10.47 | 9.11 | 7.70 | 5.32 | |
Shareholders Equity per Share |
20.76 | 20.13 | 18.73 | 16.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.76 | 20.13 | 18.73 | 16.15 | |
Free Cash Flow |
94.93 | 89.87 | 126.90 | 81.39 | |
Working Capital |
777.74 | 691.38 | 609.12 | 566.55 | |
Capital Expenditures |
(7.05) | (2.33) | 1.77 | (8.79) | |
Net Current Asset Value |
23.29 | (75.82) | (192.01) | (237.64) | |
EV/EBIT |
21.95 | 23.84 | 17.17 | 15.13 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
22.34 | 23.91 | 16.93 | 14.45 | |
| Other line items | |||||
Average Receivables |
364.47 | 345.32 | 352.95 | 351.73 | |
Average Payables |
57.00 | 44.50 | 45.37 | 38.73 | |
Average Inventory |
63.13 | 59.85 | 65.23 | 66.35 | |
Average Assets |
2,366.27 | 2,265.37 | 2,200.91 | 2,103.87 | |
Average Common Equity |
1,237.46 | 1,239.28 | 1,188.24 | 1,088.90 |
Columns are period end dates · fundamentals updated 6 Nov 2026